All In MedTech

FDA Clearance Tracker · P930014-S152

AcrySof Posterior Chamber Intraocular Lenses and Delivery Systems

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 18, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 18, 2025

Approved

Time to decision

190 days

Received Dec 10, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P930014-S152
Device name
AcrySof Posterior Chamber Intraocular Lenses and Delivery Systems
Applicant location
Fort Worth, TX
Received
Dec 10, 2024
Decided
Jun 18, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P930014

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code HQL

FDA's approval statement

As written in FDA's record.

approval for a manufacturing site located at [Alcon Huntington West Virginia, 2 Vision Lane, Lesage, West Virginia 25537 for manufacturing processes starting with injection molding and progressing through primary packaging and seal integrity testing.

Source documents

Other decisions for Alcon Laboratories, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.